冠心病心绞痛患者倍他乐克联合阿司匹林治疗的有效性及对患者血清hs-CRP、sCD40L、IL-6水平的影响

Efficacy of betaloc combined with aspirin in patients with coronary heart disease and angina pectoris and its effect on serum hs-CRP,sCD40L and IL-6 levels.

目的探讨冠心病心绞痛患者倍他乐克联合阿司匹林治疗的有效性及对患者血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、可溶性CD40配体(sCD40L)水平的影响。方法前瞻性选取2019年1月至2020年2月期间玉林市第一人民医院收治的冠心病心绞痛患者100例作为研究对象,随机数字表法均分为2组。其中对照组50例患者予以阿司匹林治疗,观察组50例患者采用倍他乐克联合阿司匹林治疗。观察2组患者临床疗效,比较2组患者治疗前、治疗4周后血清hs-CRP、IL-6、sCD40L水平以及不良反应情况。结果治疗4周后,观察组临床总有效率为96.00%,明显高于对照组的82.00%,差异有统计学意义(P<0.05)。治疗前,2组患者血清hs-CRP、IL-6、sCD40L水平比较,差异无统计学意义(P>0.05)。治疗4周后,观察组患者血清hs-CRP、IL-6、sCD40L水平分别为(7.25±2.75)mol/mL、(7.55±2.46)pg/mL、(151.10±14.27)pg/mL,明显低于对照组[(8.80±2.94)mol/mL、(9.66±3.13)pg/mL、(162.38±18.43)pg/mL],差异有统计学意义(P<0.05)。观察组与对照组不良反应发生率比较(12.00%vs.8.00%),差异无统计学意义(P>0.05)。结论倍他乐克联合阿司匹林治疗冠心病心绞痛患者,可获得良好疗效,有效减轻患者血清hs-CRP、IL-6、sCD40L水平,且用药安全性较高,建议推广应用。

Objective To investigate the efficacy of betaloc combined with aspirin in patients with coronary heart disease and angina pectoris and its effect on serum concentrations of hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and soluble CD40 ligand(sCD40L).Methods From January 2019 to February 2020,100 patients with coronary heart disease and angina pectoris admitted to the First People's Hospital of Yulin City were selected as research subjects using a prospective study.They were divided into 2 groups by random number table,each group 50 cases.The control group were treated with aspirin,while the observation group were treated with betaloc combined with aspirin.The clinical efficacy of the 2 groups of patients was observed,and the serum hs-CRP,IL-6,sCD40L levels and adverse reactions of the 2 groups before treatment and 4 weeks after treatment were compared.Results After 4 weeks of treatment,the total clinical effective rate of the observation group was 96.00%,which was significantly higher than that of the control group(82.00%),the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in serum hs-CRP,IL-6,and sCD40L levels between the two groups(P>0.05).After 4 weeks of treatment,the levels of hs-CRP,IL-6 and sCD40L in the observation group were(7.25±2.75)mol/mL and(7.55±2.46)pg/mL,(151.10±14.27)pg/mL respectively,which were significantly lower than those in the control group[(8.80±2.94)mol/mL,(9.66±3.13)pg/mL,(162.38±18.43)pg/mL],the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(12.00%vs.8.00%)(P>0.05).Conclusion Betaloc combined with aspirin for patients with coronary heart disease and angina pectoris can achieve good efficacy,effectively reduce the serum hS-CRP,IL-6,sCD40L in patients,and the drug safety is relatively high,it is recommended to promote the application.